Xiang-Yang Wang

University of Virginia School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

This 23-color mouse immunophenotyping panel was designed and developed by the Virginia Commonwealth University’s (VCU) flow cytometry shared resource (FCSR) to easily bring new use to our high-parameter spectral cytometers. Our method is broadly applicable to multiple tissue types, is modifiable, and provides a reproducible, cost-effective option for utilizing high-parameter flow cytometry. To facilitate the mouse immunophenotyping panel, researchers can be provided with optimized reagents, a step-by-step staining protocol, instrument training, pre-run single-color controls, and acquisition and analysis templates to streamline the workflow. Data analysis is generally done with a traditional manual gating strategy, but t-stochastic neighbor embedding (tSNE) and uniform manifold approximation projection (uMAP) generation can be performed, as desired. In an FCSR, this panel requires only light preparation work for shared resource (SR) staff with maximum benefit for researchers. Overall, this publication describes how SR facilities can provide additional benefits and services to their clientele by reducing costs, increasing reproducibility, and lowering the barriers of entry for researchers into the field of high parameter spectral flow cytometry. The panel described is used as an example of the application of the included methods, as well as a complete resource for other institutions to utilize themselves.

Year:

2026

Year:

2026

Traumatic brain injury (TBI) is a significant risk factor for the development of Alzheimer’s disease (AD) and related dementia. In both TBI and AD, inflammation plays a pivotal role. Recent studies have found that TBI triggers activation of NLRP3 inflammasome in the brain whereas the NLRP3 inflammasome plays an important role in pathogenesis of AD. To evaluate the influence of TBI on the immune response and the importance of the NLRP3 inflammasome in mediating this process we have examined the immune profiles in the brain using a novel transgenic AD mouse line with the NLRP3 gene deleted. Briefly, a group of 3xTg and 3xTg/NLRP3 -/- mice received a moderate TBI in the form of lateral fluid percusive injury FPI or sham surgery at the age of 4 months old, an age before the onset of AD. Injury-induced changes in immune profiling were assessed using flow cytometry, real-time quantitative PCR, or Western blot at the acute and subacute stages following TBI. We found that TBI altered immune profiles in 3xTg mice and NLRP3 gene knock out counteracts the injury effect with a significant sex-related difference. More specifically, at the acute stage after TBI in both male and female mice, TBI induced a significant infiltration of neutrophils, macrophages and γδ T-cells in the brains of 3xTg mice, however, NLRP3 knock down significantly blocked this injury effect in males and less so in females. We also found that NLRP3 gene knock down counteracted TBI-enhanced inflammatory cytokine IL1-β, TNF-α, and IL-17f expression. The abnormal immune profiling was not significant at 7 days post-injury, however, changes in cerebral vascular associated proteins including GFAP, AQP4, CD31, Occludin were observed in related to injury, NLRP3 and sex. In conclusion, our study has confirmed that TBI significantly alters immune profiles and vascular integrity in the context of predisposition of AD and the NLRP3 inflammasome is important in mediating these TBI-induced changes. Sex-related differences warrant further evaluation to define the role of NLRP3-related immune response and vascular pathology as a result to TBI and the predisposition to AD development.

Year:

2026

Background/Objectives: Preclinical and clinical evidence supports a chaperone-based vaccination platform for cancer immunotherapy. The objective of this study is to interrogate the next generation of chaperone-based immune modulator, termed Flagrp170, which was constructed by fusing a defined NF-κB-activating microbial sequence with a large stress protein with a superior antigen-holding/presenting property in the setting of antigen-targeted cancer vaccination. Methods: Bone marrow-derived dendritic cells were treated with Flagrp170 protein or an unmodified parental chaperone molecule (i.e., Grp170), followed by an analysis of DC activation and DC-mediated T cell priming using both in vitro and in vivo models. Antitumor vaccine responses in mice receiving tumor antigens (e.g., gp100, Her2/neu) complexed with Flagrp170 or Grp170 were examined through multiple immune assays. The potential use of a Flagrp170-based chaperone vaccine to sensitize tumors to anti-PD-1 therapy was also evaluated. Results: Flagrp170 not only retains the intrinsic ability of the parent chaperone to facilitate antigen cross-presentation, but also acquires a unique capacity to stimulate DCs efficiently through the engagement of TLR5-NF-κB signaling. This chimeric chaperone shows superior activity compared to the unmodified parental molecule, resulting in enhanced DC activation and T cell priming. Vaccination with Flagrp170 complexed to tumor antigens induces a robust T cell response against primary tumors and metastases, a process critically dependent on CD8+ DCs. Additionally, the Flagrp170 chaperone vaccine can efficiently generate and expand tumor-reactive T cells. The consequent remodeling of the tumor microenvironment towards a Th1/Tc1 dominant immune phenotype significantly potentiates cancer responsiveness to anti-PD1 therapy. Conclusions: Given the safety and T cell stimulation profiles of the chaperone–antigen complex vaccine already established in our recent clinical trial, this new generation of chaperone cargo, capable of delivering both antigenic targets and pathogen-associated immunoactivating signals simultaneously, represents a promising strategy to potentially improve the low response rates in patients receiving immune checkpoint inhibitors.

Year:

2025

Year:

2025

Reciprocal interactions between breast cancer cells and the tumor microenvironment (TME) are important for cancer progression and metastasis. We report here that the deletion or inhibition of sphingosine kinase 2 (SphK2), which produces sphingosine-1-phosphate (S1P), markedly suppresses syngeneic breast tumor growth and lung metastasis in mice by creating a hostile microenvironment for tumor growth and invasion. SphK2 deficiency decreased S1P and concomitantly increased ceramides, including C16-ceramide, in stromal fibroblasts. Ceramide accumulation suppressed activation of cancer-associated fibroblasts (CAF) by upregulating stromal p53, which restrained production of tumor-promoting factors to reprogram the TME and to restrict breast cancer establishment. Ablation of p53 in SphK2-deficient fibroblasts reversed these effects, enabled CAF activation and promoted tumor growth and invasion. These data uncovered a novel role of SphK2 in regulating non–cell-autonomous functions of p53 in stromal fibroblasts and their transition to tumor-promoting CAFs, paving the way for the development of a strategy to target the TME and to enhance therapeutic efficacy. Significance: Sphingosine kinase 2 (SphK2) facilitates the activation of stromal fibroblasts to tumor-promoting cancer-associated fibroblasts by suppressing host p53 activity, revealing SphK2 as a potential target to reprogram the TME.

Year:

2025

There is a significant sex bias in lung cancer, with males showing increased mortality compared with females. A better mechanistic understanding of these differences could help identify therapeutic targets to personalize cancer therapies to each sex. After observing a clear sex bias in humanized mice, with male patient-derived xenograft lung tumors being more progressive and deadlier than female patient-derived xenograft lung tumors, we identified mouse tumor models of lung cancer with the same sex bias. This sex bias was not observed in models of breast, colon, melanoma, and renal cancers. In vivo , the sex bias in growth and lethality required intact ovaries, functional innate NK cells and monocytes/macrophages, and the activating receptor NKG2D. Ex vivo cell culture models were sensitized to the anticancer effects of NKG2D-mediated NK cell and macrophage killing through the TRAIL–Bcl-XL axis when cultured with serum from female mice with intact ovaries. In both flank and orthotopic models, the Bcl-XL inhibitor navitoclax (ABT-263) improved tumor growth control in female mice and required NK cells, macrophages, and the TRAIL signaling pathway. This research suggests that navitoclax and TRAIL pathway agonists could be used as a personalized therapy to improve outcomes in women with lung cancer. Significance: Lung cancers in females are more susceptible to killing through a TRAIL–Bcl-XL axis, indicating that targeting this axis therapeutically could represent a personalized approach to treat female patients with lung cancer.

Year:

2024

Background and Aim: Drug-induced liver injury occurs frequently and can be life threatening. Although drug-induced liver injury is mainly caused by the direct drug cytotoxicity, increasing evidence suggests that the interplay between hepatocytes and immune cells can define this pathogenic process. Here, we interrogate the role of the pattern recognition scavenger receptor A (SRA) for regulating hepatic inflammation and drug-induced liver injury. Approach and Results: Using acetaminophen (APAP) or halothane-induced liver injury models, we showed that SRA loss renders mice highly susceptible to drug hepatotoxicity, indicated by the increased mortality and liver pathology. Mechanistic studies revealed that APAP-induced liver injury exaggerated in the absence of SRA was associated with the decreased anti-inflammatory and prosurvival cytokine IL-10 concomitant with excessive hepatic inflammation. The similar correlation between SRA and IL-10 expression was also seen in human following APAP uptake. Bone marrow reconstitution and liposomal clodronate depletion studies established that the hepatoprotective activity of SRA mostly resized in the immune sentinel KCs. Furthermore, SRA-facilitated IL-10 production by KCs in response to injured hepatocytes mitigated activation of the Jun N-terminal kinase-mediated signaling pathway in hepatocytes. In addition, supplemental use of IL-10 with N -acetylcysteine, only approved treatment of APAP overdose, conferred mice improved protection from APAP-induced liver injury. Conclusion: We identify a novel hepatocyte-extrinsic pathway governed by the immune receptor SRA that maintains liver homeostasis upon drug insult. Giving that drug (ie, APAP) overdose is the leading cause of acute liver failure, targeting this hepatoprotective SRA-IL-10 axis may provide new opportunities to optimize the current management of drug-induced liver injury.

Year:

2023

Collaborators (16)

Sheldon Milstien

Professor

Virginia Commonwealth University

UNITED STATES
View details

Victoria Findlay

Associate Professor with Tenure

Virginia Commonwealth University

UNITED STATES
View details

Dipankar Bandyopadhyay

Virginia Commonwealth University

UNITED STATES
View details

Raghavendra Pillappa

-

UNITED STATES
View details

Paula Bos

Associate Professor

Virginia Commonwealth University

UNITED STATES
View details

Sarah Spiegel

-

UNITED STATES
View details

Dong Sun

Professor

Virginia Commonwealth University

UNITED STATES
View details

Joseph Landry

Associate Professor

Virginia Commonwealth University

UNITED STATES
View details

Anthony Faber

Professor

Virginia Commonwealth University

UNITED STATES
View details

Hongxia Wang

Research assistant professor

Virginia Commonwealth University Medical Center

UNITED STATES
View details

Howard Li

Physician/Assistant Chief of Pulmonary

Oscar G. Johnson VA Medical Center

UNITED STATES
View details

Masoud H. Manjili

Professor

University of Virginia School of Medicine

UNITED STATES
View details

Cynthia Weigel

Virginia Commonwealth University

UNITED STATES
View details

Mikhail Dozmorov

Associate professor

Virginia Commonwealth University

UNITED STATES
View details

Rebecca Martin

Associate Professor

Virginia Commonwealth University

UNITED STATES
View details

Jennifer Koblinski

Assistant professor, Director Cancer Mouse Models Core

Virginia Commonwealth University

UNITED STATES
View details